TVTX - Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today? | Benzinga
Travere Therapeutics Inc (NASDAQ: TVTX) announced topline two-year confirmatory secondary endpoint results from its head-to-head Phase 3 PROTECT Study of Filspari (sparsentan) in IgA nephropathy (IgAN) versus Sanofi SA's (NASDAQ: SNY) Avapro (irbesartan).
Filspari demonstrated long-term kidney function preservation and achieved a clinically meaningful difference in estimated glomerular filtration rate (eGFR) total and chronic slope versus irbesartan, narrowly missing statistical significance in eGFR total slope ...